Caribou Biosciences CRBU 深 滬
已收盤 12-19 16:00:00 美东时间
1.68
+0.050
+3.07%
華盛通- 最 高1.70
- 今 開1.64
- 成交量 186.56万股
- 最 低 1.62
- 昨 收 1.63
- 總市值 1.56亿
- 52周最高 3.535
- 市盈率 靜 --
- 換手率 2.00%
- 52周最低 0.66
- 委 比 -73.30%
- 總股本 9312.32万
- 歷史最高 32.645
- 量 比 1.73
- 振 幅 4.91%
- 歷史最低 0.66
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
Caribou Biosciences will host a panel discussion at the 67th ASH Annual Meeting to explore how vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, can expand access for patients with second-line large B cell lymphoma, particularly in community settings. The event, moderated by Tina Albertson, MD, PhD, will feature insights from leading physicians and discuss vispa-cel's safety, efficacy, and potential to improve treatment accessibility. Vispa-...
12-01 21:05
Caribou Biosciences Q3 EPS $(0.30) Beats $(0.36) Estimate, Sales $2.198M Miss $2.650M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.2 percent. This is a 21.05 percent increase over losses of $(0.38) per share
11-13 05:20
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
1. Caribou Biosciences报告了2025年第三季度财务结果，截至2025年9月30日拥有1.592亿美元现金、现金等价物和市场证券。 2. Vispa-cel在ANTLER 1期试验中显示疗效和安全性与自体CAR-T疗法相当，有望成为同类最佳异基因CAR-T疗法。 3. CB-011在CaMMouflage 1期试验中表现出深度和持久反应，成为治疗复发性多发性骨髓瘤的潜在最佳异基因CAR-T疗法。 4. 研发费用下降至2240万美元，管理费用下降至920万美元，净亏损扩大至2.7545亿美元。
11-12 21:05
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
3 Penny Stocks to Watch Now, 11/4/25
Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are ...
11-04 23:49
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
Caribou Biosciences will hold a webcast on November 3, 2025, at 8:00 am ET, to present new data from its ANTLER phase 1 trial for vispacabtagene regedleucel (vispa-cel), an allogeneic anti-CD19 CAR-T therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and initial data from its CaMMouflage phase 1 trial for CB-011, an allogeneic anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma. The company will also discuss plans for...
11-02 21:00
CORRECTION: Caribou Biosciences Q2 Adj. EPS $(0.35) Beats $(0.39) Estimate, Sales $2.667M Beat $2.465M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.39) by 9.09 percent. This is a 16.67 percent increase over losses of $(0.42) per share
08-13 06:33
Caribou Biosciences Regains Nasdaq Compliance
Caribou Biosciences ( ($CRBU) ) just unveiled an update. On June 18, 2025, Cari...
06-24 02:41
Caribou Biosciences Confirms Director Elections and Auditor
The latest announcement is out from Caribou Biosciences ( ($CRBU) ). On June 12...
06-14 04:50
